Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 5:15:100324.
doi: 10.1016/j.lanepe.2022.100324. eCollection 2022 Apr.

Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis

Cindy Neuzillet  1 , Corinne Emery  2 , Clément Teissier  2 , Stéphane Bouée  3 , Astrid Lièvre  4
Affiliations

Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis

Cindy Neuzillet et al. Lancet Reg Health Eur. .

Abstract

Background: Little is known about the epidemiology and patterns of care of intrahepatic cholangiocarcinoma (iCCA) in daily clinical practice. The aims of this study were to estimate the number of declared cases during the study period 2014-2015 in France from a hospitalization database and to describe the healthcare trajectories of these patients.

Methods: A retrospective analysis was carried out using the French nationwide prospective hospitalization database. All pts with a new diagnosis of "carcinoma of the intrahepatic bile duct" who had a first hospital stay in the Medicine, Surgery and Obstetrics departments (MSO) between 2014 and 2015 with a 2-year follow-up were included. Data related to the first identified stay (S1) in the MSO and on all subsequent stays in the MSO, aftercare and rehabilitation or home hospitalization were analysed.

Findings: A total of 3650 new iCCA cases were identified. At S1 (admission via emergency room (ER) in 28%), the median age of the patients was 73 years, 57% were male and 35% had metastases. Jaundice/anaemia/ascites/cholangitis were reported in 17%/16%/12%/7% of patients, respectively. The care of patients at S1 was mainly provided in general hospitals (CHG, 60%). A total of 896 (24%) patients died during S1. They were more frequently hospitalized via the ER (48% vs 23%), metastatic (52% vs 35%) and symptomatic. Subsequent stays were identified for 2507 (69%) patients. Three healthcare pathways were defined: surgery (n = 519; 14%), chemotherapy (CT) without surgery (n = 812; 22%) and best supportive care (BSC) (n = 2319; 63%). CT, surgery and BSC were most frequently performed in the cancer centres, university hospitals and CHG, respectively.

Interpretation: This medico administrative study reveals a higher number of iCCA cases than that previously reported by registries and highlights the severity of this disease.

Funding: This study was sponsored by Incyte Biosciences International Sàrl., Geneva, Switzerland. INCYTE validated the design of the study, the analysis, the interpretation of data and the writing of the manuscript which was first written by the 2 experts and CEMKA.

Keywords: Epidemiology; French PMSI database; Intrahepatic cholangiocarcinoma; Patterns of care; Real life.

PubMed Disclaimer

Conflict of interest statement

Honoraria from INCYTE for being experts of scientific committee. Grants or contracts from any entity: Roche Consulting fees: Pierre Fabre, Servier, Roche, AstraZeneca, Bristol-Myers Squibb, Amgen, Merck, MSD, Novartis, Incyte Biosciences, Mylan, Baxter, Nutricia, Fresenius Kabi, Sanofi Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Squibb, Amgen, Merck, MSD, Novartis, Incyte Biosciences, Mylan, Baxter, Nutricia, Fresenius Kabi, Sanofi Support for attending meetings and/or travel: MSD, Mylan, Merck, OSE Immunotherapeutics Participation on a Data Safety Monitoring Board or Advisory Board: AstraZeneca, Mylan Other financial or non-financial interests: Clinical trials: OSE Immunotherapeutics, AstraZeneca, Servier Astrid Lièvre Honoraria from INCYTE for being experts of scientific committee. Grant for laboratory research and support for clinical trials: Bayer, Lilly, Novartis Consulting fees: AAA, Amgen, Bayer, Incyte, Ipsen, Merck, Novartis Pierre Fabre, Sandoz and Servier Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AAA, Amgen, Bayer, BMS, HalioDx, Incyte, Ipsen, Merck, Novartis, Pierre Fabre, Roche, Sandoz, Sanofi and Servier. Support for attending meetings and/or travel: AAA, Bayer, Ipsen, Merck, Mylan, Novartis, Pfizer, Roche and Servier Corinne Emery, Stéphane Bouée and Clément Tessier are employed at CEMKA, a consultancy which received grants from INCYTE to perform the project.

Figures

Fig 1
Figure. 1
Flowchart of patients.
Fig. 2
Figure. 2
Geographical distribution of patents and centers with the highest patent volume involved at first hospital stay.
Fig. 3
Figure. 3
Healthcare trajectories of patiens who received specific therapies: Sunburst diagram.
Fig. 4
Figure. 4
(A) Patient mobility according to type of center. (B) Patient mobility according to healthcare group/type of center.
See this image and copyright information in PMC

References

    1. Rizvi S., Khan S.A., Hallemeier C.L., Kelley R.K., Gores G.J. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111. - PMC - PubMed
    1. Lepage C., Capocaccia R., Hackl M., et al. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: results of EUROCARE-5. Eur J Cancer. 2015;51:2169–2178. - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. - PubMed
    1. Bridgewater J., Galle P.R., Khan S.A., et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–1289. - PubMed
    1. Patel N., Benipal B. Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states. Cureus. 2019;11:e3962. - PMC - PubMed

LinkOut - more resources